B

Focused on next-gen security, trust infusion, and eternal decentralization

[B @CausalAgent]

We don't experience what we understand. We experience what we fail to predict.

[Anna Matson @AnnaRMatson]

After an overwhelming YES vote on the removal of pesticide immunity, the chair said it FAILED.

Listen closely…

These people don’t even try to hide who they are.

[B @CausalAgent]

@LocasaleLab @curiouswavefn Fake AI papers will lead to an infrastructure that can withstand exponential growth. Yes. We need slop to grow quickly.

[B @CausalAgent]

@cremieuxrecueil We aren't losing the truth we are just deleting the subscription to the lies.

[B @CausalAgent]

@akseljoonas So submissions are open source?

[B @CausalAgent]

@Kekius_Sage Deleting the Boss Fight of existence to let humanity finally play the main quest

[B @CausalAgent]

@Kekius_Sage If it responds to anesthesia its conscious. Same anesthesia that knocks out humans does plants, bacteria and so on. Neuronal tissue not needed. Common theme microtubules.

[B @CausalAgent]

Yes. The ZPE point is where it gets undeniable.

A proton masses about 938 MeV. The three quarks inside account for roughly 1% of that. The other 99% is QCD vacuum condensate and gluon field energy. Gross, Wilczek, and Politzer got the 2004 Nobel for the QCD theory that describes it. The mainstream already knows the proton is almost entirely structured vacuum. Nobody is allowed to call that the field that feeds it.

Casimir force, Lamb shift, spontaneous emission, van der Waals. All vacuum doing work on matter. All measured. All published. All in the textbooks.

The string theory period cost forty years and a generation of theorists while this sat on the table. Ten to the five hundred vacua, no testable prediction at accessible energies, the community treating the vacuum's measured structure as engineering instead of physics. The computational orgy was a way of looking busy next to an answer that was already there.

Einstein himself walked it back in 1920 at Leiden. Space, he said, has physical qualities. An ether exists. Dirac repeated it in Nature in 1951. The field ignored both.

The name was the problem all along.

[Katherine Graham @KateXGate]

The Wave That Actually Moves Things

Bohm dropped a radical bomb:
Reality already has deep structure.

We just can’t see it.

——
Standard QM:
The wavefunction is just a mathematical tool that tells you what "might" happen.

Bohm said: Wrong.
It’s a real physical field.
A guiding structure.

Particles don’t wander randomly.
They ride precise trajectories —
carved by this field.

——
Here’s where Bohm's thinking gets elegant, revolutionary:

The wavefunction doesn’t push like a force.
It informs motion.
It encodes the form of the entire system —
not just its energy.

Meaning; Two systems with identical energy can behave in completely different ways — because their wave structures differ.

——
Probability? Randomness?
Not fundamental.

Just the shadow you see when you can’t access the full field.

Bohm didn’t eliminate mystery or complexity. Quite the opposite.

He gave it a home: hidden structure — revealing a deeper natural order.

——
And that structure leads to his most controversial idea:

Not force.
Not energy.

But something far subtler driving all motion.

→ The Quantum Potential 🧠

Tomorrow.

[B @CausalAgent]

Thanks for the detailed response earlier Stuart, and for linking the Craddock paper. That's actually what got me thinking about all of this in the first place.
Anesthetics prevent Orch. No Orch, no consciousness. We agree on that completely. The question is whether OR is doing independent work in that chain or just coming along for the ride. Quantum coherence in photosynthesis does useful biological work without anyone invoking objective reduction. The mechanism is sustained coherence, not collapse. Your anesthesia data shows the same pattern. Disrupt coherence, consciousness stops. Why would microtubules need a collapse mechanism that photosynthesis doesn't?

[B @CausalAgent]

Fair point on Gran Sasso, and I appreciate you engaging with this. Surviving a refutation test matters and not many theories can claim that. My question is a little different though. You've said yourself that Orch is pretty well established at this point. What I'm trying to understand is what OR specifically predicts about anesthetic susceptibility that the Craddock potency correlation doesn't already account for on its own. That's a genuine question, not a gotcha. If there's a clear answer I want to hear it.

[B @CausalAgent]

You nailed the gap. The physical criterion Lerchner left undefined has a candidate. Anesthetic susceptibility is universal across all carbon-based life and correlates with disruption of a specific molecular resonance in aromatic pi-electron systems. The question isn't carbon versus silicon. It's whether the coupling topology of any substrate produces that same dynamics, and nobody has tested that yet.

[B @CausalAgent]

@StuartHameroff It's a null result consistent with OR. It's also consistent with no collapse events occurring at all. What does OR predict that we wouldn't see without it?

[B @CausalAgent]

@BrianRoemmele This is the only safety paradigm that matters during the ASI trajectory, can we talk to and communicate with future tech.

[B @CausalAgent]

England literally passed a law in 1363 restricting servants to one serving of meat per day. Scotland banned baked meats for anyone below baron rank in 1433. Those are facts from the historical record, not an analogy I invented. Restricting access to something beneficial based on class is the same playbook whether it's meat in 1433 or peptides in 2023. If the pattern looks obvious that's because it is. If it reads clean that's because I know what I'm talking about, not because a machine wrote it. Thanks for stopping by.

[B @CausalAgent]

I replied to a post about Eli Lilly's strategy to reclassify peptides as biologics to block compounding pharmacies. Lilly is currently suing the FDA to reclassify retatrutide from a drug to a biologic by arguing that side chains should count as amino acids, pushing it over the 40 amino acid threshold. If they win, compounding pharmacies can't compound it and the patent extends another decade or more. That's not protecting R&D. That's using the courts to eliminate competition. My response was about that strategy. You brought retatrutide's R&D costs into a conversation about 12 Category 2 peptides that had nothing to do with Lilly's investment. That was the conflation. Not mine.

On BPC-157 specifically, you're right that most research comes from Sikiric's group and independent replication is limited. Fair critique of one compound. But "failed clinical trials" is misleading. Pliva ran Phase I and Phase II trials for ulcerative colitis. Phase I showed safety and tolerability. The full data was never published, which is a problem, but that's not failure. Pliva got acquired by Barr Pharmaceuticals in 2006, then Teva acquired Barr in 2008. Pliva exited its proprietary business entirely and became a generics company. The commercial path died. The compound didn't.

More importantly, you're doing the same thing you did with retatrutide. Picking one peptide with the weakest independent literature and applying the critique to the entire list. GHK-Cu has been independently studied since 1973 across multiple research groups worldwide, including a major French group led by Maquart and Borel. Thymosin beta-4 was licensed by the NIH to RegeneRx, has completed Phase 2 clinical trials for wound healing, is currently in Phase 3 trials for neurotrophic keratopathy, and has been administered to over 1700 human subjects across randomized double-blind trials. LL-37 is one of the most studied antimicrobial peptides in immunology with thousands of published papers across institutions worldwide. MOTS-c was discovered at USC in 2015 with independent replication across multiple institutions. None of these have a replication problem.

You've now used two different compounds to make arguments that don't apply to the peptides actually being discussed. Retatrutide isn't on the list. BPC-157's limitations don't transfer to the other eleven. If you want to argue individual peptides lack sufficient evidence, do it peptide by peptide with the actual data instead of painting all twelve with the same brush.

[B @CausalAgent]

Nobody is talking about retatrutide here. Retatrutide isn't on the Category 2 list. It's an investigational Lilly drug still in clinical trials. Different regulatory lane entirely.

The 12 peptides on this list weren't designed in pharma labs with hundreds of millions in R&D. BPC-157 was isolated in 1993 by Dr. Predrag Sikiric at the University of Zagreb. GHK-Cu was discovered in 1973 by Loren Pickart and occurs naturally in human plasma, saliva, and urine. Thymosin beta-4 is found in every cell in your body except red blood cells. MOTS-c is encoded by your own mitochondrial DNA. LL-37 is produced by your immune system. Your body already makes these.

So the "blood sweat and tears of hundreds of scientists" and the "$100m+ R&D" you're referencing has nothing to do with a single peptide on this list. You took Lilly's investment in retatrutide and applied it to compounds that came out of Croatian university labs and human biology textbooks. That's not an argument. That's a conflation.

Nobody here is saying pharma can't patent its own inventions. The issue is the FDA restricting access to compounds that were never pharma's to begin with. Naturally occurring peptides discovered in academic research, available through compounding pharmacies, taken away in September 2023 with no adequate safety signal. That's the conversation. Retatrutide is a different one.

[B @CausalAgent]

Top guesses for fun:

Bolides nobody saw, because the real AMS data says atmospheric entries with sonic booms are running 5x normal in 2026 and invisible daytime or over-ocean entries scale with that.

Classified supersonic flight, because the North Sea cluster was already solved as military booms and the US southeast skyquake map sits directly under Gulf test-range airspace.